Kindred Biosciences Inc (NASDAQ:KIN), one of the top biopharmaceutical providers has made an important announcement. It has unveiled an underwritten public offering of 3,000,000 shares outlining that each share will be going at a public offering of about $7.50.

The total offering will be amounting to about $22.5 million before the deduction of the underwriting discounts as well as the associated commissions. There was also a close assessment of the estimated offering expenses payable by the provider.

Kindred Biosciences Inc has over the years involved itself in saving as well as improving the lives of pets. The company has given a window of about 30 days to the underwriters to proceed and make purchases of about 450,000 more shares of its common stock. The provider has expressed its commitment to offering all the shares.

One of the people familiar with the matter disclosed that by July 17, 2017 the offering will already have come to an end. As a matter of fact that will be in close consideration to the various existing customary conditions.

According to Yahoo, KindredBio is looking forward to using the net proceeds resulting from the offering. It also anticipates the approval as well as the launch of future products. One of the top officials working with the company has expressed much optimism. They have affirmed that the development of the company’s therapeutic candidates will help the company make tremendous steps forward in business.

While recently speaking to one of the media houses, one of the top executives working with the provider said, “The shares are being offered pursuant to an effective shelf registration statement on Form S-3, as amended (File No. 333-201553), that was previously filed with the Securities and Exchange Commission (SEC) and declared effective on January 30, 2015. A prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC’s website.”

It might seem like everything moves quite smoothly for Kindred Biosciences Inc. However, it is important to outline that the company has also had its fair share of challenges to get to where it stands at the moment.